The X-ray crystal structure and hydrogen-bonding patterns of the title compound, C18H17N3O3.C5H5N, a non-N-alkylated cyclotripeptide containing one alpha- and two beta-amino acids, are reported. The amides in the 11-membered ring have an unprecedented all-transoid configuration. The torsion angles and Dunitz parameters describing non-planarity of the amides contained in the cyclotripeptide are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1107/S0108270106041242 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Importance of infarct topography in determination of stroke mechanism and recurrence risk: a post-hoc analysis of the dabigatran acute treatment of stroke trial.
BMJ Open
January 2025
School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia
Objective: To evaluate the relationship between infarct pattern, inferred stroke mechanism and risk of recurrence in patients with ischaemic stroke. The question is clinically relevant to optimise secondary stroke prevention investigations and treatment.
Design: We conducted a retrospective analysis of the dabigatran treatment of acute stroke II (DATAS II) trial (ClinicalTrials.
Unsupervised clustering approach to assess heterogeneity of treatment effects across patient phenotypes in randomized clinical trials.
Contemp Clin Trials
January 2025
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, United States of America.
Background: Primary results from randomized clinical trials (RCT) only inform on the average treatment effect in the studied population, and it is critical to understand how treatment effect varies across subpopulations. In this paper we describe a clustering-based approach for the assessment of Heterogeneity of Treatment Effect (HTE) over patient phenotypes, which maintains the unsupervised nature of classical subgroup analysis while jointly accounting for relevant patient characteristics.
Methods: We applied phenotype-based stratification in the ENGAGE AF-TIMI 48 trial, a non-inferiority trial comparing the effects of higher-dose edoxaban regimen (direct anticoagulant) versus warfarin (vitamin K antagonist) on a composite endpoint of stroke and systemic embolism in 14,062 patients with atrial fibrillation.
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study.
Contemp Clin Trials
January 2025
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore, MD, USA.. Electronic address:
Background: As people with cystic fibrosis (PWCF) live longer due to the breakthrough drug elexacaftor-tezacaftor-ivacaftor (ETI), they have questioned whether other CF therapies could be safely discontinued. SIMPLIFY was the first prospective, randomized trial to evaluate non-inferiority of discontinuing versus continuing two therapies. The QUEST (Qualitative Understanding of Experiences in the SIMPLIFY Trial) study was conducted to understand experiences of PWCF enrolled in SIMPLIFY, including why they joined, perceptions of randomization, decision-making around study withdrawal, and considerations for future discontinuation studies.
View Article and Find Full Text PDFAssociation of constipation with the survival of patients with idiopathic interstitial pneumonias.
Respir Investig
November 2024
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.
Background: Constipation is associated with the prognosis of several chronic diseases. However, the effect of constipation on the prognosis of idiopathic interstitial pneumonias (IIPs) remains unclear. This study aimed to investigate the association between constipation and the prognosis of patients with IIPs.
View Article and Find Full Text PDFTRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer.
Proc Natl Acad Sci U S A
October 2024
Department of Pathology, Suzhou Medical College of Soochow University, Soochow University, Suzhou 215123, China.
Article Synopsis
- - KRAS mutations lead to aggressive tumors and drug resistance in colorectal cancer, making treatment difficult, particularly with targeted therapies like regorafenib.
- - TRIM21, influenced by ERK2 and KRAS signaling, plays a key role in regulating c-Myc, which affects glycolysis and contributes to resistance to regorafenib.
- - Targeting TRIM21 to inhibit its phosphorylation may improve treatments for KRAS-mutant colorectal cancer, with the antidepressant vilazodone showing promise in enhancing the effectiveness of regorafenib in research models.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!